{Reference Type}: Journal Article
{Title}: COVID-19 in hospitalized solid organ transplant recipients in a nationwide registry study.
{Author}: Moreno-Torres V;Martínez-Urbistondo M;Calderón-Parra J;Mills P;Muñoz-Serrano A;Arias-Milla A;Benítez L;Aguilar-Pérez M;Múñez-Rubio E;Ramos-Martínez A;Fernández-Cruz A;Cuervas-Mons V;de Mendoza C;
{Journal}: Int J Infect Dis
{Volume}: 134
{Issue}: 0
{Year}: 2023 Sep 14
{Factor}: 12.074
{DOI}: 10.1016/j.ijid.2023.06.007
{Abstract}: OBJECTIVE: Underlying immunodeficiency has been associated with worse clinical presentation and increased mortality in patients with COVID-19. We evaluated the mortality of solid organ transplant (SOT) recipients (SOTR) hospitalized in Spain due to COVID-19.
METHODS: Nationwide, retrospective, observational analysis of all adults hospitalized because of COVID-19 in Spain during 2020. Stratification was made according to SOT status. The National Registry of Hospital Discharges was used, using the International Classification of Diseases, 10th revision coding list.
RESULTS: Of the 117,694 adults hospitalized during this period, 491 were SOTR: kidney 390 (79.4%), liver 59 (12%), lung 27 (5.5%), and heart 19 (3.9%). Overall, the mortality of SOTR was 13.8%. After adjustment for baseline characteristics, SOTR was not associated with higher mortality risk (odds ratio [OR] = 0.79, 95% confidence interval [CI] 0.60-1.03). However, lung transplantation was an independent factor related to mortality (OR = 3.26, 95% CI 1.33-7.43), while kidney, liver, and heart transplantation were not. Being a lung transplant recipient was the strongest prognostic factor in SOT patients (OR = 5.12, 95% CI 1.88-13.98).
CONCLUSIONS: This nationwide study supports that the COVID-19 mortality rate in SOTR in Spain during 2020 did not differ from the general population, except for lung transplant recipients, who presented worse outcomes. Efforts should be focused on the optimal management of lung transplant recipients with COVID-19.